Cancer Family
Malignant Musculoskeletal Neoplasm
CI-CAN-00000242Explore in graph →
141 active trials5 approved drugs46 evidence items
- NCIt
- C166357
Loading cancer entity…
Cancer Family
CI-CAN-00000242Explore in graph →
Clinical trials
465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (58)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07830667 | A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat | not yet recruiting | Phase 1 / Phase 2 | 79 | Children's Oncology GroupNETWORK | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07819838 | Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | not yet recruiting | Phase 1 / Phase 2 | 77 | Children's Oncology GroupNETWORK | 0 | Sep 15, 2026 |
| clinicaltrials |
| NCT07560410 | Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) | not yet recruiting | Phase 1 / Phase 2 | 10 | China Medical University HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07224568 | Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors(INTERCEPT) | not yet recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Nov 4, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials